About Biolidics Limited

Incorporated in 2009, **Biolidics** is a Singapore-based medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring.

Biolidics has developed the ClearCell® FX1 System, a fully automated IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood.

Biolidics' ClearCell® FX1 System allows users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood samples or perform further analysis on cancer cells.

Liquid biopsies (i.e. analysis of the circulating tumour cells in blood samples) have many applications throughout the various stages of a patient's cancer journey, from cancer screening and staging to personalised treatment, and post-cancer monitoring.

Biolidics' quality assurance capabilities have been recognized through its ISO certification. Europe: CE-marked. North-America: The ClearCell® FX1 System is registered with the US FDA Class 1 medical device. The ClearCell® FX1 Run Kits are for "Research Use Only" – not for use in diagnostic procedures.

Ordering Information

Biolidics Limited
81 Science Park Drive #02-03, The Chadwick
Singapore Science Park 1, Singapore 118257
+65 6482 0668 sales@biolidics.com
www.biolidics.com

Biolidics



Choose Live
Tolerate No Labels
ClearCell® FX1 System

Enrichment Solution for Circulating Tumour Cells

Biolidics

Bringing Clarity to Cancer

Technology

Liquid Biopsy is a **simple and minimally invasive** alternative to surgical biopsies which enables doctors to obtain more information about the disease with a simple blood draw. The information obtained from the blood draw including circulating tumors cells can provide valuable information for cancer patient disease management. It enables the understanding of cancer heterogeneity in a patient, providing more holistic information about the disease.

The ClearCell® FX1 System, a **fully automated** cell enrichment medical device for cell retrieval that can separate and enrich **wholly intact and viable** Circulating Tumour Cells, or CTCs from whole blood. This results in high consistent recovery.



Principle :

The ClearCell® FX1 System is driven by CTChip® FR which enrich CTCs based on size and deformability.

Through the process of Dean Flow Fractionation (DFF), cell relocate and distribute themselves within the channel of the CTChip® FR1. The formation of the Dean vortex flows present in the biochip results in larger cells to be located along the inner wall and the smaller cells along the outer wall. The enrichment process is completed by siphoning the large cell stream into our collection outlet as the enriched circulating tumor cell fraction.

Therefore the ClearCell FX1 offers a high purity, continuous separation solution for CTC enrichment.

Workflow



7.5ml blood sample is collected in EDTA/Streck blood collection tube

Red blood cell lysis is performed

CTC enrichment is performed on the ClearCell® FX1 System

Enriched CTC output ready for downstream analysis

Downstream Applications

The potential downstream applications of the CTCs enriched using ClearCell® FX1 System include the following:

Cell culture

Experimental therapeutics

Cytopathology

Cellular examination of microscope level

Genomics

DNA/RNA genetic analysis

Immunofluorescence

Characterisation by IF





Cytogenetics

Detection of genetic anomaly by FISH